Prospective study of glucagon and incretin secretion in patients with diabetes

Prospective study of glucagon and incretin secretion in patients with diabetes - Prospective study of glucagon and incretin secretion in patients with diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000055737

Enrollment

120

Registered

2024-12-01

Start date

2021-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Arginine 30 g IV over 30 minutes and measure blood glucose, insulin, C-peptide, glucagon, GLP-1, and GIP before loading, 10, 20, 30, 40, 50, 60, 90, and 120 minutes.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 1, type 2, or other type of diabetes patients (including pancreatic diabetes) between 18 and 90 years of age and those with normal glucose tolerance who are attending our hospital. 1-A) Normal glucose tolerance is defined as a fasting blood glucose of less than 110 mg/dl or HbA1c of less than 6.2% at a checkup within the past year. (2) Those whose attending physician has determined that they can tolerate an arginine stimulation test. (3) Hemoglobin (Hb) levels of at least 11.3 g/dL.

Exclusion criteria

Exclusion criteria: (1) Persons strongly suspected of suffering from dementia or psychiatric disorders (2) Those who are using drugs that affect glucagon and GLP-1 secretion, such as GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. (3) Persons with severe renal or hepatic dysfunction (4) Persons with bronchial asthma that is difficult to control (5) Persons deemed inappropriate for this clinical research by the Principal Investigator or a Research Supervisor.

Design outcomes

Primary

Measure	Time frame
Increment of glucagon and GLP-1 secretion by arginine stimulation test	—

Secondary

Measure	Time frame
Correlation between increment of glucagon or GLP-1 and HbA1c, age, gender, clinical indices such as diabetes mellitus type, disease duration, blood pressure, and laboratory tests (blood count, blood glucose, Cre, BUN, uric acid, AST, ALT, ALP, gamma-GTP, LDH, CK, TP, Alb, T-Cho, LDL-C, HDL-C, TG, Amy, Lipa, T-Bil, Na, K, Cl, Ca, urine qualitative, urine sediment, urine protein, urine Alb /Cre as examined at the examination)	—

Measure

Time frame

Correlation between increment of glucagon or GLP-1 and HbA1c, age, gender, clinical indices such as diabetes mellitus type, disease duration, blood pressure, and laboratory tests (blood count, blood glucose, Cre, BUN, uric acid, AST, ALT, ALP, gamma-GTP, LDH, CK, TP, Alb, T-Cho, LDL-C, HDL-C, TG, Amy, Lipa, T-Bil, Na, K, Cl, Ca, urine qualitative, urine sediment, urine protein, urine Alb /Cre as examined at the examination)

—

Countries

Japan

Contacts

Public ContactRyota Usui

Kansai Electric Power Medical Research Institute Yutaka Seino Distinguished Center for Diabetes Research

usui0605@kuhp.kyoto-u.ac.jp0664585821

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026